Is the Current Diagnosis of Schizophrenia Useful or Harmful?


In recent decades, evidence has appeared in various scientific fields—genetic, psychopharmacological, neuro-psychological, etc.—which makes it difficult to maintain the positive and negative syndrome of schizophrenia under one and the same diagnosis. On the other hand, there are social and legal reasons recommending the conception of these two syndromes as different entities. In this paper, we conduct appropriate bibliographical researches to reveal these evidences. We discuss these findings and conclude proposing the split of positive and negative syndromes of schizophrenia in two different disorders.

Share and Cite:

J. Alvarez-Rodriguez, S. Alvarez-Silva and I. Alvarez-Silva, "Is the Current Diagnosis of Schizophrenia Useful or Harmful?," Open Journal of Medical Psychology, Vol. 3 No. 2, 2014, pp. 157-160. doi: 10.4236/ojmp.2014.32018.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] I. Berman, B. Viegner, A. Merson, E. Allan, D. Pappas and A. I. Green, “Differential Relationships between Positive and Negative Symptoms and Neuropsychological Deficits in Schizophrenia,” Schizophrenia Research, Vol. 25, No. 1, 1997, pp. 1-10.
[2] R. W. Buchanam, “Persistent Negative Symptoms in Schizophrenia: An Overview,” Schizophrenia Bulletin, Vol. 33, No. 4, 2007, pp. 1013-1022.
[3] J. Kennard, “Paranoid Schizophrenia. Health Guide,” 2008.
[4] S. I. Cohen, “Overdiagnosis of Schizophrenia: Role of Alcohol and Drug Misuse,” Lancet, Vol. 346, No. 8989, 1995, pp. 1541-1541.
[5] A. Mestdagh and B. Hansen, “Stigma in Patients with Schizophrenia Receiving Community Mental Health Care: A Review of Qualitative Studies,” Social Psychiatry and Psychiatric Epidemiogy, 2013.
[6] E. Bleuler, “Dementia Praecox or the Group of Schizophrenias,” International University Press, New York, 1950.
[7] R. Cancro and A. A. Sugerman, “Classification and Outcome in Process-Reactive Schizophrenia,” Comprehensive Psychiatry, Vol. 9, No. 3, 1968, pp. 227-232.
[8] J. Phillips and J. Phillips, “Diagnosing Schizophrenia from DSM-II to DSM-5: A Quiz,” Psychiatric Times, 2011.
[9] H. I. Kaplan, B. J. Sadock and J. A. Greeb, “Kaplan and Sadock’s Synopsis of Psychiatry. Behavioral Sciences/ Clinical Psychiatry,” Williams & Wilkins, Baltimore, 1994.
[10] N. J. Bray, P. R. Buckland, H. J. Williams, N. Norton, M. J. Owen and M. C. O’Donovan, “A Halotype Implicated in Schizophrenia Susceptibility Is Associated with Reduced COMT Expression in Human Brain,” American Journal of Human Genetics, Vol. 73, No. 1, 2003, pp. 152-161.
[11] P. J. Harrison and D. R. Weinberger, “Schizophrenia Genes, Gene Expression, and Neuropathology: On the Matter of Their Convergence,” Molecular Psychiatry, Vol. 10, No. 1, 2005, pp. 40-68.
[12] N. C. Allen, S. Bagade, M. B. McQueen, J. P. Ioannidis, F. K. Kavvaoura, M. J. Kkoury, R. E. Tanzi and J. Bertram, “Systematic Meta-Analyses and Field Synopsis of Genetic Association Studies in Schizophrenia: The SzGene Database,” Nature Genetics, Vol. 40, No. 7, 2008, pp. 827-834.
[13] K. Gallander, “Neurobiological and Genetic Markers in Schizophrenia: A Theoretical Replication Using the Allen Institute for Brain Sciences Online Database,” Faculty of Humboldt State University, Arcata, 2012.
[14] Cross-Disorder Group of Psychiatric Genomics Consortium, “Identification of Risk Loci with Shared Effects on Five Major Psychiatric Disorders: A Genome-Wide Analysis,” Lancet, Vol. 381, No. 9875, 2013, pp. 1371-1379.
[15] A. H. Fanous and K. S. Kendler, “Genetics of Clinical Features ANS Subtypes of Schizophrenia: A Review of the Recent Literature,” Current Psychiatry Reports, Vol. 10, No. 2, 2008, pp. 164-170.
[16] R. W. Heinrichs and K. K. Zakzanis, “Neurocognitive Deficit in Schizophrenia: A Quantitative Review of the Evidence,” Neuropsychology, Vol. 12, No. 3, 1998, pp. 426-445.
[17] M. Cannon, A. Caspi, T. E. Moffit, H. Harrington, A. Taylor, R. M. Murray and R. Poulton, “Evidence for Early-Childhood, Pan-Developmental Impairment Specific to Schizopreniphorm Disorder: Results from a Longitudinal Cohort,” Archives of General. Psychiatry, Vol. 59, No. 5, 2002, pp. 446-456.
[18] R. Penadés, C. Gastó, T. Boget., R. Catalán and M. Salamanero, “Deficit in Schizophrenia: The Relationship between Negative Symptoms and Neurocognition,” Comprehensive Psychiatry, Vol. 42, No. 1, 2001, pp. 64-69.
[19] J. Kantrowitz and D. C. Javvit, “Glutamatergic Transmission in Schizophrenia: From Basic Research to Clinical Practice,” Current Opinion in Psychiatry, Vol. 25, No. 2, 2012, pp. 96-102.
[20] S. M. Stahl, “Beyond the Dopamine Hypothesis to the NMDA Glutamate Receptor Hypofunction Hypothesis of Schizophrenia,” CNS Spectrums, Vol. 12, No. 4, 2007, pp. 265-268.
[21] A. Marsman, M. P. van den Heuvel, D. W. Klomp, R. S. Kahn, P. R. Luijten and H. E. Hulshoff Pol, “Glutamate in Schizophrenia: A Focused Review and Meta-Analysis of 1H_RMS Studies,” Schizophrenia Bulletin, Vol. 39, No. 1, 2011, pp. 120-129.
[22] R. D. Paz, S. Tardito, M. Atzoin and K. Y. Tseng, “Glutamatergic Dysfunction in Schizophrenia: From Basic Neuroscience to Clinical Psychopharcology,” European Neuropsychopharmacology, Vol. 18, No. 11, 2008, pp. 773-786.
[23] S. Ghose, K. A. Gleason, B. W. Potts, K. Lewis-Azmezcua and C. A. Tamminga, “Differential Expression of Glutamate Receptors 2 and 3 in Schizophrenia: A Mechanism for Antipsychotic Drug Action?” American Journal of Psychiatry, Vol. 166, No. 7, 2009, pp. 812-820.
[24] J. T. Coyle and G. Tsai, “The NMDA Receptor Glycine Modulatory Site: A Therapeutic Target for Improving Cognition and Reducing Negative Symptoms in Schizophrenia,” Psychopharmacology, Vol. 174, No. 1, 2004, pp. 32-38.
[25] D. C. Goff and J. T. Coyle, “The Emerging Role of Glutamate in the Pathophysioloy and Treatment of Schizophrenia,” American Journal of Psychiatry, Vol. 158, No. 9, 2001, pp. 1367-1377.
[26] R. Bennet, G. R. Hughes, E. G. Bywaters and P. H. Holt, “Neuropsychiatric Problems in Systemic Lupus Erithematosus,” British Medical Journal, Vol. 4, 1972, pp. 342-345.
[27] J. Paris, “Why Psychiatrists Are Reluctant to Diagnose: Borderline Personality Disorder,” Psychiatry (Edgmont), Vol. 4, No. 1, 2007, pp. 35-39.
[28] S. Pizzarello and J. Taylor, “Peer Substance Use Associated with the Co-Occurrence of Borderline Personality Disorder Features and Drug Use Problems in College Students,” Journal of College American Health, Vol. 59, No. 5, 2011, pp. 408-414.
[29] A. Paparelli, M. Di Forti, P. D. Morrison and R. M. Murray, “Drug-Induced Psychosis: How to Avoid Star Gazing in Schizophrenia Research by Looking at More Obvious Sources of Light,” Frontiers in Behavioral Neuroscience, Vol. 5, 2011, p. 1.
[30] T. O. Affi, C. A. henriksen, G. J. Asmudson and J. Sareen, “Victimization and Perpetration of Intimate Partner Violence and Substance Use Disorders in a Nationally Representative Sample,” Journal of Nervous and Mental Disease, Vol. 200, No. 8, 2012, pp. 648-691.
[31] C. A. Wishman and C. Y. Shonbrun, “Social Consequences of Borderline Personality Disorder Symptoms in a Population-Based Survey: Marital Distress, Marital Violence, and Marital Disruption,” Journal of Personality Disorders, Vol. 23, No. 4, 2009, pp. 410-415.

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.